Extended Data Fig. 5: Pathologic features in patients with LN involvement.
From: Association between pathologic response and survival after neoadjuvant therapy in lung cancer

Pathologic features (histology, tumor PD-L1 status, tumor tissue TMB, and TRAEs) for the path-evaluable population with LN involvement in the nivolumab plus chemotherapy (n = 68) and chemotherapy (n = 74) arms. LN denotes lymph node; mut/Mb, mutations/megabase; NA, not available; PD-L1, programmed death ligand 1; RVT, residual viable tumor; TMB, tumor mutational burden; TRAE, treatment-related adverse event. aMedian %RVT for nivolumab plus chemotherapy was 25.0% (squamous), 50.0% (nonsquamous), 70.0% (PD-L1 < 1%), 25.0% (PD-L1 1–49%), 0 (PD-L1 ≥ 50%), 5.0% (PD-L1 NA), 90.0% (TMB < 12.3 mut/Mb), 8.0% (TMB ≥ 12.3 mut/Mb), 17.5% (TMB NA), 32.5% (TRAEs grade 1/2), 84.0% (TRAEs grade 3/4), and 0 (No TRAE). bMedian %RVT for chemotherapy was 83.5% (squamous), 99.5% (nonsquamous), 85.0% (PD-L1 < 1%), 99.5% (PD-L1 1–49%), 97.5% (PD-L1 ≥ 50%), 100% (PD-L1 NA), 96.0% (TMB < 12.3 mut/Mb), 100% (TMB ≥ 12.3 mut/Mb), 88.5% (TMB NA), 93.0% (TRAEs grade 1/2), 95.0% (TRAEs grade 3/4), and 100% (No TRAE).